Es gab 50 kürzliche Insider-Transaktionen für Femasys Inc. (FEMY), darunter 40 Käufe und 1 Verkauf. Die gesamten Insider-Käufe beliefen sich auf $1.52M und die gesamten Insider-Verkäufe auf $6.25M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Canning John Charles, Elefant Dov, Lee-sepsick Kathy. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — FEMY
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
Unbekannt |
- |
- |
- |
30,000 |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
RSU-Zuteilung |
150,000 |
$0.38 |
$57K |
150,000 |
| 2026-03-19 |
Elefant Dov |
Chief Financial Officer |
RSU-Zuteilung |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU-Zuteilung |
68,244 |
$0.58 |
$39.58K |
68,244 |
| 2026-03-19 |
Larsen Charles |
Director |
RSU-Zuteilung |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Eichenbaum Kenneth D. |
Director |
RSU-Zuteilung |
102,366 |
$0.58 |
$59.37K |
102,366 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
RSU-Zuteilung |
35,200 |
$0.60 |
$21.12K |
35,200 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
Unbekannt |
- |
- |
- |
25,010 |
| 2026-03-17 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
Unbekannt |
- |
- |
- |
- |
| 2026-03-17 |
Silverman Joshua |
Director |
Unbekannt |
- |
- |
- |
- |
| 2026-02-19 |
Elefant Dov |
Chief Financial Officer |
RSU-Zuteilung |
169,000 |
- |
- |
169,000 |
| 2026-02-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU-Zuteilung |
282,000 |
- |
- |
282,000 |
| 2026-02-02 |
Sipos Jeremy Alexander |
Chief Technology Officer |
RSU-Zuteilung |
80,000 |
- |
- |
80,000 |
| 2025-12-16 |
Sipos Jeremy Alexander |
Chief Technology Officer |
Unbekannt |
3,334 |
$6.12 |
$20.4K |
- |
| 2025-11-07 |
Elefant Dov |
Chief Financial Officer |
Ermessenskauf |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Larsen Charles |
Director |
Ermessenskauf |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Lee-sepsick Kathy |
Chief Executive Officer |
Ermessenskauf |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Eichenbaum Kenneth D. |
Director |
Unbekannt |
102,366 |
$1.10 |
$112.6K |
- |
| 2025-08-27 |
Elefant Dov |
Chief Financial Officer |
Ermessenskauf |
38,828 |
$0.52 |
$20K |
38,828 |
| 2025-08-27 |
Lee-sepsick Kathy |
Chief Executive Officer |
Ermessenskauf |
48,535 |
$0.52 |
$25K |
48,535 |
| 2025-06-25 |
Silverman Joshua |
Director |
RSU-Zuteilung |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Uzialko Edward R |
Director |
RSU-Zuteilung |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Larsen Charles |
Director |
RSU-Zuteilung |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Milnes Alistair |
Director |
RSU-Zuteilung |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
Unbekannt |
- |
- |
- |
45 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
RSU-Zuteilung |
100,000 |
$0.90 |
$90K |
100,000 |
| 2025-06-02 |
Elefant Dov |
Chief Financial Officer |
Ermessenskauf |
19,608 |
$1.02 |
$20K |
19,608 |
| 2025-06-02 |
Lee-sepsick Kathy |
Chief Executive Officer |
Ermessenskauf |
34,314 |
$1.02 |
$35K |
312,092 |
| 2025-06-02 |
Currie Daniel Scott |
Chief Operating Officer |
Ermessenskauf |
19,608 |
$1.02 |
$20K |
86,275 |
| 2025-06-02 |
Larsen Charles |
Director |
Ermessenskauf |
24,510 |
$1.02 |
$25K |
56 |
| 2025-01-29 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU-Zuteilung |
59,849 |
$1.17 |
$70.02K |
59,849 |
| 2025-01-28 |
Elefant Dov |
Chief Financial Officer |
RSU-Zuteilung |
72,045 |
$1.05 |
$75.65K |
72,045 |
| 2025-01-28 |
Currie Daniel Scott |
Chief Operating Officer |
RSU-Zuteilung |
29,184 |
$1.05 |
$30.64K |
29,184 |
| 2025-01-28 |
Thomas Christine E |
Chief Reg & Clinical Officer |
RSU-Zuteilung |
23,600 |
$1.05 |
$24.78K |
23,600 |
| 2024-07-12 |
Silverman Joshua |
Director |
RSU-Zuteilung |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Uzialko Edward R |
Director |
RSU-Zuteilung |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Larsen Charles |
Director |
RSU-Zuteilung |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Milnes Alistair |
Director |
RSU-Zuteilung |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-02-12 |
Spector Richard D. |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-02-12 |
Spector Richard D. |
Chief Commercial Officer |
RSU-Zuteilung |
100,000 |
$1.10 |
$110K |
100,000 |
| 2024-02-01 |
Elefant Dov |
Chief Financial Officer |
RSU-Zuteilung |
84,000 |
$0.80 |
$67.2K |
84,000 |
| 2024-02-01 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU-Zuteilung |
204,900 |
$0.80 |
$163.92K |
204,900 |
| 2024-02-01 |
Currie Daniel Scott |
Chief Operating Officer |
RSU-Zuteilung |
61,900 |
$0.80 |
$49.52K |
61,900 |
| 2024-02-01 |
Thomas Christine E |
SVP, Regulatory & Clinical |
RSU-Zuteilung |
32,600 |
$0.80 |
$26.08K |
32,600 |
| 2023-11-21 |
Silverman Joshua |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2023-11-21 |
Silverman Joshua |
Director |
RSU-Zuteilung |
17,000 |
$0.90 |
$15.3K |
17,000 |
| 2023-11-21 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
Veräußerung |
4,237,288 |
$1.48 |
$6.25M |
- |
| 2023-10-10 |
Thomas Christine E |
SVP, Regulatory & Clinical |
RSU-Zuteilung |
60,000 |
$1.76 |
$105.6K |
60,000 |
| 2023-07-03 |
Elefant Dov |
Chief Financial Officer |
RSU-Zuteilung |
105,200 |
$0.49 |
$51.55K |
105,200 |
| 2023-07-03 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU-Zuteilung |
270,400 |
$0.49 |
$132.5K |
270,400 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
